T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by aberrant proliferation of immature thymocytes. Despite an overall survival of 80% in the pediatric setting, 20% of patients with T-ALL ultimately die from relapsed or refractory disease. Therefore, there is an urgent need for novel therapies. Molecular genetic analyses and sequencing studies have led to the identification of recurrent T-ALL genetic drivers. This review summarizes the main genetic drivers and targetable lesions of T-ALL and gives a comprehensive overview of the novel treatments for patients with T-ALL that are currently under clinical investigation or that are emerging from preclinical research.
CITATION STYLE
Cordo, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2021, January 1). T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies. Blood Cancer Discovery. American Association for Cancer Research Inc. https://doi.org/10.1158/2643-3230.BCD-20-0093
Mendeley helps you to discover research relevant for your work.